Arbutus Biopharma Corporation Common Stock (ABUS) is a publicly traded Healthcare sector company. As of May 20, 2026, ABUS trades at $4.36 with a market cap of $823.73M and a P/E ratio of 5.20. ABUS moved +3.81% today. Year to date, ABUS is -7.22%; over the trailing twelve months it is +36.14%. Its 52-week range spans $2.71 to $5.10. Rallies surfaces ABUS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Which politicians traded ABUS stock?
Rallies tracks politician and congressional stock disclosures for ABUS, including purchases, sales, transaction dates, owners, and reported trade amounts when available.
HASTINGS DAVID C sold 22.18K (~$72.83K) on Feb 4, 2025.
Sims Karen sold 19.35K (~$63.52K) on Feb 4, 2025.
McElhaugh Michael J. sold 23.79K (~$78.10K) on Feb 4, 2025.
ABUS Analyst Consensus
ABUS analyst coverage data. Average price target: $0.00.
Common questions about ABUS
Which politicians traded ABUS stock?
Rallies tracks politician and congressional stock disclosures for ABUS, including purchases, sales, transaction dates, owners, and reported trade amounts when available.
Does Rallies track congressional trades in ABUS?
Yes. Rallies tracks politician and congressional stock disclosures for ABUS, including reported purchases, sales, dates, owners, and trade amounts when available.
Is ABUS research on Rallies investment advice?
No. Rallies provides research, data, and educational context for ABUS. It does not provide personalized investment advice.
